[Relation between the duration of the chronic phase of chronic myeloid leukemia and total dose of busulfan in the first year of the treatment].
The analysis was based on 31 patients with chronic granulocytic leukaemia (CGL) treated during the period 1975-1986 and the correlation between the total dose of busulphan administered during the first year of treatment and the duration of chronic phase of the disease was investigated. We found such correlation and also we found that the duration of the chronic phase was more significantly correlated with one year maintenance dose of busulphan. This suggests that the prognosis in CGL is more connected with the proliferation activity of leukaemic cells than with the extent of disease at the time of diagnosis.
Hellmann
A
A
III Kliniki Chorób Wewnetrznych ICHW AM w Gdańsku.
Koberda
J
J
Baran
W
W
D000328:Adult; D000368:Aged; D002066:Busulfan / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D013997:Time Factors
D002066:Busulfan
Zalezność czasu trwania fazy przewlekłej przewlekłej białaczki szpikowej od rocznej dawki busulfanu w pierwszym roku leczenia.